Respiratory Infections Market

Upper respiratory infections are one of the major reasons for outpatient patient visits to hospitals. Upper respiratory infections occur at the upper region of the respiratory tracts. Particular areas which are primarily affected by the infection include nasal cavity, sinuses, pharynx, and trachea. The Nonprescription Upper respiratory infections drugs are one of the common treatment available in the market.

Availability of wide range of medicated products and treatment options are available on the go. Resulting in the OTC medication based market comprising more than 80% of all upper respiratory tract drugs. The wide availability of drugs and comparative low pricing is anticipated drive the Nonprescription Upper Respiratory Infections market.

The lenient regulations from the US Food and Drug Administration for OTC drugs is anticipated to lure new manufacturers in the Nonprescription Upper Respiratory Infections market. Additionally, product launches, research, and developments from key manufacturers in Nonprescription Upper Respiratory Infections market are evolving into product segments. Example: - the launch of Otrivin nasal spray (Xylometazoline) from Novartis led to similar product launch from another key market player. 

The significantly high incidence of the common cold is one of the prime conditions of the upper respiratory infections, sequentially anticipated to be one of the prime factors for the Nonprescription Upper respiratory infections market growth. Sudden and persistent climate changes coupled with increasing severity of air pollution is anticipated to be one the prime factor increasing the incidence of upper respiratory infection.

Thereby increasing URI patient pool and demand for Nonprescription Upper respiratory infections drugs. The higher demand for Nonprescription Upper respiratory infections drugs is primarily arising from developing and developed countries due to growing customs of self-medication.

The higher demand is projected to bolster the growth for Nonprescription Upper respiratory infections market. Lifestyle changes and inclination towards personal hygiene is anticipated to boost the demand for preventive treatment drug.

Subsequently, aiding the growth for Nonprescription Upper Respiratory Infections market. However, excessive abusive consumption and major adverse effects related to the nonprescription upper respiratory infections drugs is restraining the growth of the nonprescription upper respiratory infections market. 

• Nonprescription Upper Respiratory Infections Market Segments
• Nonprescription Upper Respiratory Infections Market Dynamics
• Historical Actual Market Size, 2013 - 2017
• Nonprescription Upper Respiratory Infections Market Size & Forecast 2018 to 2026
• Nonprescription Upper Respiratory Infections Agents Current Trends/Issues/Challenges
• Competition & Companies involved
• Nonprescription Upper Respiratory Infections Market Drivers and Restraints

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance